HealthCare Ventures

HealthCare Ventures, established in 1985 and headquartered in Cambridge, Massachusetts, is a prominent venture capital firm focused on early-stage investments in the life sciences and healthcare sectors. The firm primarily targets pre-clinical and early clinical stage companies that demonstrate the potential to enhance patient care. With a specialization in biotechnology, HealthCare Ventures invests in various therapeutic areas, including cancer, cardiovascular diseases, central nervous system disorders, infectious diseases, and immunotherapy. The firm aims to support the development of innovative products and technologies that can transform medical practices and improve pharmaceutical manufacturing. Typically, HealthCare Ventures invests between $4 million and $12 million in privately owned companies within North America, fostering advancements in healthcare that align with its mission.

James H. Cavanaugh

Managing Director, Senior Advisors and Partner, Fund III-VIII

Augustine Lawlor

Managing Director

John Littlechild

General Partner

Marla K. McMillan

Vice President, Finance

Christopher Mirabelli

Managing Director

Douglas Onsi

Managing Director

Robert Steinberg

Vice President, Operations

Jeffrey Steinberg

VP of Legal Affairs

Harold Werner

Co-Founder, Managing Director, Senior Advisors and Fund III-VIII Partner

107 past transactions

Cleveland HeartLab

Series B in 2012
Cleveland HeartLab, Inc. is a specialty clinical laboratory and disease management company focused on novel biomarker technologies and the creation of proprietary diagnostic tests.
Advancis is a pharmaceutical company focused on developing and commercializing novel anti-infective products.

Replidyne

Series A in 2002
Replidyne is a specialty pharmaceutical company focused on developing and commercializing innovative anti-infective products. The company is building its development pipeline based on both its proprietary DNA replication technology and in-licensing efforts.
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

Cardiokine

Series B in 2006
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.

Catalyst Biosciences

Series B in 2006
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

Sequoia Pharmaceuticals

Series C in 2007
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

CellGate

Series E in 2003
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).

Proteostasis Therapeutics

Series B in 2015
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.

Radius Health

Series C in 2008
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Xanthus Pharmaceuticals

Series B in 2003
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

InfaCare Pharmaceutical

Series B in 2008
InfaCare Pharmaceutical, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceuticals for the neonatal and pediatric patient population. Its neonatal product, Stanate, is under development for the pharmacologic treatment of infantile jaundice or hyperbilirubinemia. The company was founded in 2005 and is based in Trevose, Pennsylvania.
RedPath Integrated Pathology, LLC operates as a reference laboratory and provides support services for oncology cases. It offers PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen. The company serves pathologists, clinicians, and patients. RedPath Integrated Pathology, LLC was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
MiddleBrook Pharmaceuticals is a pharmaceutical company offering anti-infective products and antibiotics.

More.com

Series C in 1999
More.com is an online health, beauty, and wellness store.

Vaxxas

Series A in 2011
Vaxxas Pty. Ltd. develops and commercializes vaccine delivery technologies. It offers Nanopatch platform that induces immune system activation by targeting vaccine to the abundant immunological cells below the surface of the skin. Vaxxas Pty. Ltd. was incorporated in 2011 and is based in Sydney, Australia with an additional office location in Cambridge, Massachusetts.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Cellnovo

Series B in 2011
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Sequoia Pharmaceuticals

Series B in 2005
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.

Cool Energy

Venture Round in 2011
Cool Energy, Inc. engages in developing systems that use renewable energy sources to provide carbon-free power production. The company develops SolarHeart engine that converts operational lower temperature waste heat into electricity. Its SolarHeart engine captures waste heat that an industrial site, commercial process, or power generator is already emitting, and turns it into clean and renewable electricity, recycled thermal energy, or mechanical energy. The company’s product could be used in various waste heat recovery settings, including commercial and industrial facilities, remote and military generators, biomass, solar thermal, and geothermal. Cool Energy, Inc. was founded in 2006 and is headquartered in Boulder, Colorado.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Stemgent

Debt Financing in 2009
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem

Vaxxas

Series B in 2015
Vaxxas Pty. Ltd. develops and commercializes vaccine delivery technologies. It offers Nanopatch platform that induces immune system activation by targeting vaccine to the abundant immunological cells below the surface of the skin. Vaxxas Pty. Ltd. was incorporated in 2011 and is based in Sydney, Australia with an additional office location in Cambridge, Massachusetts.

nanoMR

Series B in 2011
nanoMR has developed the first system for rapid isolation of rare cells from complex matrices at levels of 1 cell/mL or lower. The immunomagnetic capture system can target multiple cell types simultaneously, for example capturing bacteria and fungi from bloodstream infections, or specific cell types, such as circulating tumor, or fetal, cells, in less than 30 minutes.

Xanodyne

Series A in 2007
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Orqis Medical

Series C in 2003
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

Theraclone Sciences

Venture Round in 2010
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Xanthus Pharmaceuticals

Series B in 2006
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

Dynogen Pharmaceuticals

Series A in 2002
Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

Trevena

Series B in 2010
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Theraclone Sciences

Venture Round in 2011
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

SkinMedica

Series D in 2004
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Colorescience

Series B in 2014
Colorescience, Inc. produces and sells mineral-based cosmetics and sun screen products. It offers treatment products, UV protectors, primers, foundations, and enhancers. The company’s products are used to treat pigmentation, redness, dark circles, and aging problems, as well as sensitive, oily, and dry skin. It sells its products through a network of licensed physicians and luxury spas, retailers, and distributors; as well as online. The company was founded in 2000 and is based in Carlsbad, California. Colorescience, Inc. is a former subsidiary of SkinMedica, Inc.

Anchor Therapeutics

Series B in 2010
Anchor Therapeutics, Inc., a discovery and pre-clinical development-stage biopharmaceutical company, develops pharmaceutical candidates to address cancer, inflammation, metabolism, heart disease, and pain. The company develops Pepducin lipopeptide drug candidates, which are molecules that target the intracellular domains of G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling. Its Pepducin technology platform is used to develop lipopeptide allosteric modulators for intractable GPCR targets. The company was formerly known as Ascent Therapeutics, Inc. and changed its name to Anchor Therapeutics, Inc. in March 2010. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.

VaxInnate

Series C in 2006
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Orqis Medical

Series D in 2007
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

Seahorse Bioscience

Series D in 2009
Seahorse Bioscience provides analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The company's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.

Leap Therapeutics

Venture Round in 2016
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.

Galleon Pharmaceuticals

Series B in 2015
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.

NitroMed

Series E in 2001
NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.

Xanodyne

Venture Round in 2004
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

ActivBiotics

Series A in 2002
ActivBiotics develops and sells antibiotics and combination therapies for the treatment of acute and chronic infections. The company’s lead product candidate, Rifalazil, is a proprietary, orally administered antibacterial agent which is in a Phase III clinical trial for the treatment of intermittent claudication associated with peripheral arterial disease. The company’s other product candidate, M40403, is a proprietary small molecule to mimic the function of a naturally occurring enzyme, which plays a role in various inflammatory disease states. It also develops ABI-0043 as a proprietary antibacterial agent for the treatment of complicated skin and skin structure infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. In addition, the company identifies product candidates from its proprietary compound libraries for the treatment of inflammatory diseases and bacterial infections. The company’s superoxide dismutases (SOD) mimetic library consists of approximately 250 small molecules that mimic naturally occurring SOD enzymes.

Radius Health

Series C in 2011
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

BioProcessors

Series B in 2003
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Pathogenetix

Series C in 2013
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

Orqis Medical

Series B in 2001
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

Pharmathene

Post in 2009
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, a recombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland.

BioProcessors

Series C in 2006
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

CellGate

Series D in 2002
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).

CellGate

Series C in 2001
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).

Cardiokine

Series A in 2004
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

SkinMedica

Series E in 2006
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

SkinMedica

Series E in 2005
SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Dicerna Pharmaceuticals

Series B in 2010
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Avidia

Series C in 2006
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.

Aciex Therapeutics

Venture Round in 2011
Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.

Senseonics

Venture Round in 2014
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes for a period of up to 90 and 180 days. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

VaxInnate

Series B in 2004
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Foldrx Pharmaceuticals

Series B in 2006
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.

Proteostasis Therapeutics

Series A in 2008
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.

Pathogenetix

Series A in 2008
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

Stemgent

Series B in 2011
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem

Ascent Therapeutics

Series A in 2007
Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.

Pathogenetix

Series B in 2011
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

VaxInnate

Series D in 2009
VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Xanodyne

Venture Round in 2009
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Theraclone Sciences

Series B in 2013
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Pathogenetix

Series B in 2011
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.

Apellis Pharmaceuticals

Series A in 2011
Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Anexon

Seed Round in 2007
Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.

BioProcessors

Series C in 2007
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Radius Health

Private Equity Round in 2011
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Xanodyne

Series A in 2005
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Foldrx Pharmaceuticals

Venture Round in 2010
FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson's disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.

Cellnovo

Series A in 2008
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Xanthus Pharmaceuticals

Series A in 2003
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

Colorescience

Debt Financing in 2020
Colorescience, Inc. produces and sells mineral-based cosmetics and sun screen products. It offers treatment products, UV protectors, primers, foundations, and enhancers. The company’s products are used to treat pigmentation, redness, dark circles, and aging problems, as well as sensitive, oily, and dry skin. It sells its products through a network of licensed physicians and luxury spas, retailers, and distributors; as well as online. The company was founded in 2000 and is based in Carlsbad, California. Colorescience, Inc. is a former subsidiary of SkinMedica, Inc.
Their mission is to provide you with personalized, high-quality care. They are dedicated to helping you through all aspects of your neurological and surgical care. From diagnosis to management, their team is at your service, ensuring our best, for you, each and every time.

GITR

Venture Round in 2012
GITR Inc. develops therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.

Seahorse Bioscience

Series D in 2010
Seahorse Bioscience provides analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The company's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.

Trevena

Series A in 2008
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Cleveland HeartLab

Series B in 2011
Cleveland HeartLab, Inc. is a specialty clinical laboratory and disease management company focused on novel biomarker technologies and the creation of proprietary diagnostic tests.

Tensha Therapeutics

Series A in 2011
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.

Mosaic Biosciences

Series A in 2011
Mosaic Biosciences, Inc. develops biomaterials for tissue engineering applications. Its technology platform provides biomaterial for various medical applications, such as drug delivery, regenerative medicine, stem cell therapies, and sealants and adhesion barriers. Mosaic Biosciences, Inc. has a strategic collaboration with Catalyst Biosciences. The company was incorporated in 2009 and is based in Boulder, Colorado.

DecImmune Therapeutics

Venture Round in 2013
DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute tissue damaging inflammation in myocardial infarction, burns, vascular injury, and reperfusion. It develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune Therapeutics, Inc. was formerly known as Natural Antibodies, Inc. and changed its name to DecImmune Therapeutics, Inc. in September 2004. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

GlobeImmune

Series B in 2005
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Theraclone Sciences

Series B in 2007
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.